Fenebrutinib (GDC-0853, RG7845): An Orally Administered Bruton's tyrosine Kinase (BTK) Inhibitor Designed to Block B Cell Proliferation - Emerging Insights and Market Forecast to 2030 - ResearchAndMarkets.com

"FENEBRUTINIB- Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Chronic Spontaneous Urticaria in 7 Major Markets.